Group 1: Pro-Dex, Inc. (PDEX) - PDEX shares increased by 23% to close at $57.78, following a notable trading volume compared to typical sessions, despite a 12.6% loss over the past four weeks [1] - The recent surge in PDEX shares is linked to positive market sentiment due to strong financial performance and a robust business model, with over 200% return in the past six months [2] - The company is expected to report quarterly earnings of $0.38 per share, reflecting a year-over-year increase of 171.4%, with revenues projected at $13.8 million, up 9.6% from the previous year [3] Group 2: Earnings Estimates and Market Position - The consensus EPS estimate for PDEX has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - PDEX holds a Zacks Rank of 1 (Strong Buy), indicating strong investor interest and confidence in the stock [4] - In comparison, Staar Surgical (STAA), another company in the same medical-dental supplies industry, has a Zacks Rank of 3 (Hold) and has seen a decline of 3% in the past month [4][5]

Company Overview - Pro-Dex, Inc. (PDEX) has experienced rapid growth over the past year, with its valuation reaching an all-time high [1] - Founded in 1978 and headquartered in Irvine, CA, Pro-Dex specializes in tech-based solutions for various markets, including medical, dental, semiconductor, scientific research, and aerospace [2] - The company operates in multiple locations, including Santa Ana, Beaverton, OR, and Carson City, NV [2] Financial Performance - Pro-Dex has achieved a remarkable 239.7% increase in share price over the past five years, with a compound earnings per share growth of 11% per year [4] - In the first quarter of fiscal 2025, Pro-Dex reported earnings of 75 cents per share, significantly surpassing the Zacks Consensus Estimate of 29 cents [5] - The company is expected to report earnings of 38 cents per share for the next release on February 13, 2025, indicating a year-over-year increase of 171.43% [5] Market Position - Pro-Dex holds a Zacks Rank 1 (Strong Buy) and is part of the Zacks Medical – Dental Supplies industry, which is in the top 10% of all industries in the Zacks universe [3][6] - Over the past 12 months, Pro-Dex's stock has surged 193.8%, outperforming its Zacks Peer Group, which saw a rally of 171.8% [3] - The company's shares soared 23% to $57.78 on January 6, reflecting strong market confidence [4]

Financial Performance - Net sales for Q1 FY2025 increased by $3.0 million, or 25%, to $14.9 million compared to $11.9 million in Q1 FY2024[2] - Gross profit for Q1 FY2025 rose by $1.5 million, or 41%, with a gross margin increase of 4 percentage points to 35%[3] - Operating income for Q1 FY2025 increased by $1.2 million, or 64%, to $3.0 million compared to $1.8 million in the prior year[5] - Net income for Q1 FY2025 was $2.5 million, or $0.75 per diluted share, compared to a net loss of $615,000, or $0.17 per diluted share, in Q1 FY2024[6] - Unrealized gains on marketable equity investments contributed $433,000 to net income in Q1 FY2025, contrasting with unrealized losses of $2.6 million in Q1 FY2024[6] Operating Expenses - Operating expenses for Q1 FY2025 increased by $312,000, or 17%, to $2.1 million, primarily due to higher personnel costs and bonus accruals[4] Cash and Assets - Cash and cash equivalents as of September 30, 2024, were $3.1 million, up from $2.6 million at June 30, 2024[9] - Total assets increased to $54.3 million as of September 30, 2024, compared to $52.5 million at June 30, 2024[9] - Total shareholders' equity remained stable at $30.9 million as of September 30, 2024, compared to $30.9 million at June 30, 2024[9] Future Expectations - The company expects to ship production volumes of the new handpiece during the second half of FY2025[7]

Financial Performance - Net sales for the three months ended September 30, 2024, were $14.892 million, a 25% increase from $11.938 million in the same period of 2023[64] - Gross profit increased to $5.150 million, representing 35% of net sales, compared to $3.658 million or 31% of net sales in the prior year[64] - The company reported an operating income of $3.013 million, which is 20% of net sales, compared to $1.833 million or 15% in the previous year[64] - Gross profit increased by approximately $1.5 million, or 41%, for the three months ended September 30, 2024, with gross margin improving by four percentage points[72] - Operating expenses totaled $2.1 million, a 17% increase from $1.8 million in the prior year, with selling expenses rising by 92% to $48,000[73] Sales Breakdown - Medical device sales accounted for $9.912 million, or 67% of total net sales, up 27% from $7.808 million, driven primarily by orthopedic sales which increased by 38%[65][66] - Repair revenue increased by $1.1 million, or 28%, due to a higher number of repairs for orthopedic handpieces[68] - Recurring revenue from distributors of CMF drivers increased by $567,000, or 35%, compared to the same period last year[66] Costs and Expenses - Research and development costs were $843,000, representing 6% of net sales, slightly down from 7% in the prior year[64] - Cost of sales for the three months ended September 30, 2024, increased by $1.5 million, or 18%, compared to the same period in 2023, consistent with a 25% increase in revenue[71] - General and administrative expenses increased by $251,000, or 25%, primarily due to higher payroll and personnel expenses[74] - Research and development costs rose by $38,000, or 5%, driven by increased internal project spending[75] Cash Flow and Working Capital - Cash and cash equivalents increased by $450,000 to $3.1 million as of September 30, 2024, compared to $2.6 million at June 30, 2024[81] - Net cash provided by operating activities for the three months ended September 30, 2024, totaled $1.9 million, compared to $392,000 in the same period of 2023[83] - Net cash used in investing activities was $431,000 for the three months ended September 30, 2024, related to equipment purchases[85] - Net cash used in financing activities included the repurchase of $2.3 million of common stock and proceeds of $5.0 million from a new term loan[86] - Working capital as of September 30, 2024, was $27.2 million, indicating sufficient funds to meet cash requirements for at least the next 12 months[88] Future Outlook - The backlog at September 30, 2024, was approximately $56.8 million, with $45.6 million scheduled for delivery during the remainder of fiscal 2025[70] - The company expects production shipments of the next generation handpiece to ramp up in the third and fourth quarters of fiscal 2025[66] - Discounts and other increased by $126,000 due to volume rebates related to the orthopedic handpiece[69]

Core Insights - Pro-Dex, Inc. reported strong financial results for Q4 fiscal 2024, with net income of $1.6 million or 46 cents per share, an increase from 42 cents per share year-over-year [1][3] - Quarterly net sales surged by 41% to $15 million, up from $10.6 million in the same quarter last year, driven by a $3.4 million revenue increase from the largest customer [2][8] - The company faced challenges in maintaining gross margin levels, which contracted from 32% to 27%, attributed to price pressures and rising indirect labor costs [4][9] Quarterly Performance Overview - Operating expenses remained stable at $1.7 million, with a strategic reduction in general and administrative costs and a slight increase in engineering expenses [5] - Operating income rose by 46% year-over-year to $2.4 million, reflecting effective operational adjustments and sales initiatives [5] - The financial health of Pro-Dex indicates a strategic enhancement in operational execution, despite the impact of unrealized gains and losses on investments [3][9] Balance Sheet Update - As of June 30, 2024, Pro-Dex's cash and cash equivalents decreased to $2.6 million from $2.9 million at the end of the previous fiscal year [6] - Total assets increased slightly from $51.8 million to $52.5 million, while shareholders' equity decreased from $31.6 million to $30.9 million [6] Cash Flows - Pro-Dex generated $6.2 million in operating cash flows for fiscal 2024, an increase from $5.5 million in the prior year [7] Fiscal 2024 Update - Annual net sales increased by 17% to $53.8 million, primarily driven by recurring increases in repair and new unit sales to the primary customer [8] - Annual net income declined to $2.1 million or 60 cents per share, down from $1.95 per share in the previous year, largely due to a $4.1 million unrealized loss on marketable equity investments [9] - The year also saw a steady increase in research and development expenditures, reflecting the company's commitment to technology and product development [10]

Financial Performance - Net sales for Q4 2024 increased by $4.4 million, or 41%, to $15.0 million compared to $10.6 million in Q4 2023, driven primarily by a $3.4 million revenue increase from the largest customer[2] - Gross profit for Q4 2024 rose by $729,000, or 22%, but gross margin decreased from 32% in Q4 2023 to 27% in Q4 2024 due to price pressures and increased indirect labor costs[2] - Operating income for Q4 2024 increased by $742,000, or 46%, to $2.4 million compared to $1.6 million in Q4 2023[4] - Net income for Q4 2024 was $1.6 million, or $0.46 per diluted share, a slight increase from $1.5 million, or $0.42 per diluted share, in Q4 2023[4] - For the fiscal year 2024, net sales increased by $7.8 million, or 17%, to $53.8 million from $46.0 million in fiscal 2023, primarily due to revenue increases from the largest customer[5] - Gross profit for the fiscal year 2024 increased by $1.8 million, or 14%, to $14.5 million compared to $12.7 million in fiscal 2023[5] - Net income for the fiscal year 2024 was $2.1 million, or $0.60 per diluted share, down from $7.1 million, or $1.95 per diluted share, in fiscal 2023, impacted by unrealized losses on marketable equity investments of $4.1 million[7] - Net income for the year ended June 30, 2024, was $2,127,000, a decrease of 70% compared to $7,074,000 in 2023[11] Operating Expenses and Investments - Operating expenses for the fiscal year 2024 rose by 6% to $7.4 million from $7.0 million in the prior fiscal year, mainly due to increased research and development costs[6] - Depreciation and amortization increased to $1,160,000 from $857,000, reflecting a rise of 35%[11] - The company made an investment of $1,250,000 in Monogram during the year[11] Cash Flow and Financial Position - Net cash provided by operating activities was $6,199,000, up from $5,462,000, indicating an increase of 13.5%[11] - Net cash used in investing activities was $2,233,000, compared to $885,000 in the previous year, representing a significant increase of 152%[11] - Net cash used in financing activities totaled $4,271,000, an increase from $2,490,000, marking a rise of 71.7%[11] - Cash and cash equivalents at the end of the year were $2,631,000, down from $2,936,000, reflecting a decrease of 10.4%[11] - Accounts receivable decreased by $3,935,000, compared to an increase of $5,432,000 in the previous year[11] - Inventory increased by $898,000, contrasting with a decrease of $3,489,000 in the prior year[11] - Principal payments on notes payable were $4,816,000, down from $6,093,000, indicating a decrease of 21%[11] Strategic Focus - The company hired a new Director of Operations in Q1 fiscal 2025 to support growth, indicating a focus on operational efficiency and expansion[8] - The company continues to focus on developing new products and technologies, particularly in the orthopedic market, leveraging patented software and proprietary solutions[8]

Financial Performance - Net sales for fiscal 2024 increased by $7.8 million, or 17%, to $53.8 million compared to $46.1 million in fiscal 2023[119] - Gross profit for fiscal 2024 was $14.6 million, representing 27% of net sales, compared to $12.7 million or 28% in fiscal 2023[117] - Operating income for fiscal 2024 was $7.2 million, maintaining 13% of net sales, consistent with fiscal 2023[117] - Income before income taxes decreased to $2.6 million, or 5% of net sales, down from $9.4 million, or 20%, in fiscal 2023[117] - Net income for fiscal 2024 was $2.1 million, or 4% of net sales, compared to $7.1 million, or 15%, in fiscal 2023[117] Revenue Breakdown - Medical device revenue rose by $6.2 million, or 20%, to $37.0 million, driven by increased sales in orthopedic and CMF products[120] - Repair revenue increased by approximately $3.9 million, or 31%, to $16.5 million, attributed to refurbishments requested by the largest customer[124] - NRE and prototype services revenue decreased by $1.9 million, or 71%, due to a reduction in billable engagements[121] Expenses and Costs - Total operating expenses increased to $7.4 million, or 14% of net sales, from $7.0 million, or 15%, in fiscal 2023[117] - Total cost of sales increased by $6.0 million, or 18%, in fiscal 2024, primarily due to a 17% increase in net sales, with product costs accounting for $38.1 million, or 71% of net sales[126] - Operating expenses totaled $7.4 million in fiscal 2024, representing 14% of net sales, with selling expenses decreasing by 25% to $117,000[128] - Research and development costs rose by 14% to $3.2 million, accounting for 6% of net sales, driven by increased spending on internal product development[130] Cash Flow and Liquidity - Cash provided by operating activities was $6.2 million in fiscal 2024, with a net income of $2.1 million, despite $4.1 million in unrealized losses on equity investments[138] - As of June 30, 2024, working capital was $23.7 million, with cash and cash equivalents at $2.6 million, indicating sufficient liquidity for the next 12 months[143] Share Repurchase and Tax Rate - The company repurchased 184,901 shares at a total cost of $3.5 million during fiscal 2024, increasing total repurchases since 2013 to 1,381,349 shares at a cost of $20.7 million[147] - The effective tax rate decreased to 19% in fiscal 2024 from 25% in fiscal 2023, attributed to federal and state research credits[136] Manufacturing Costs and Backlog - The company experienced $74,000 of over-absorption of manufacturing costs in fiscal 2024, compared to $1.7 million of under-absorption in fiscal 2023[126] - The backlog as of June 30, 2024, was $19.8 million, down from $41.6 million on June 30, 2023, indicating a decline in firm purchase orders[125] Future Outlook - The company expects continued demand for enhanced repairs in fiscal 2025, although no assurances can be made regarding the volume[124] - Cash used in investing activities was $2.2 million in fiscal 2024, primarily for the exercise of the Monogram Warrant and equipment purchases[141]

Zacks Investment Research has recently initiated coverage of Pro-Dex, Inc. (PDEX) with an Outperform recommendation, signaling confidence in the company's growth prospects and financial health. Pro-Dex, a specialized manufacturer of surgical drivers and shavers primarily used in orthopedic procedures, has shown strong financial performance and strategic expansion, positioning it favorably within the competitive medical device market. Pro-Dex has reported a 10% increase in net sales year over year, reaching ...

Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2024 THIRD QUARTER AND NINE-MONTH RESULTS IRVINE, CA, May 2, 2024 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2024 with the Securities and Exchange Commission today. Quarter Ended March 31, 2024 Gross pro ...

[PART I — FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) [Financial Statements (Unaudited)](index=4&type=section&id=ITEM%201.%20FINANCIAL%20STATEMENTS%20(Unaudited)) Unaudited condensed consolidated financial statements for Q3 and 9M FY2024 are presented, detailing financial position and performance, with notes on restatement and the company's surgical device business - The financial statements for the three and nine months ended March 31, 2023, were restated to correct the estimated fair value of the Monogram Warrant, which impacted unrealized gains, income tax expense, and net income[25](index=25&type=chunk) - The company specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers, primarily for the orthopedic, thoracic, and maxocranial facial markets[32](index=32&type=chunk) [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2024, total assets were $50.5 million, a slight decrease from $51.8 million at June 30, 2023, primarily due to reduced long-term investments, while total liabilities and shareholders' equity also saw minor decreases Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2024 | June 30, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $3,219 | $2,936 | | Accounts receivable, net | $12,516 | $9,952 | | Inventory | $14,242 | $16,167 | | Total current assets | $35,957 | $30,979 | | Total assets | $50,548 | $51,823 | | **Liabilities & Equity** | | | | Total current liabilities | $10,419 | $9,676 | | Total liabilities | $19,610 | $20,233 | | Total shareholders' equity | $30,938 | $31,590 | [Condensed Consolidated Income Statements](index=5&type=section&id=Condensed%20Consolidated%20Income%20Statements) For Q3 2024, net sales increased to $14.3 million, but net income fell to $0.7 million due to an unrealized loss on investments, while for the nine-month period, net sales grew to $38.8 million, but net income significantly decreased to $0.5 million due to a $3.8 million unrealized loss Income Statement Summary (in thousands, except per share amounts) | Metric | Q3 2024 | Q3 2023 (restated) | 9M 2024 | 9M 2023 (restated) | | :--- | :--- | :--- | :--- | :--- | | Net sales | $14,293 | $13,079 | $38,819 | $35,448 | | Gross profit | $4,002 | $3,811 | $10,462 | $9,390 | | Operating income | $2,213 | $2,065 | $4,822 | $4,152 | | Net income | $655 | $1,617 | $540 | $5,572 | | Diluted EPS | $0.19 | $0.45 | $0.15 | $1.52 | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the nine months ended March 31, 2024, net cash provided by operating activities increased to $5.2 million, while net cash used in investing and financing activities also increased, resulting in an overall cash and cash equivalents increase of $283,000 Cash Flow Summary for Nine Months Ended March 31 (in thousands) | Activity | 2024 | 2023 (restated) | | :--- | :--- | :--- | | Net cash provided by operating activities | $5,179 | $4,835 | | Net cash used in investing activities | ($2,126) | ($733) | | Net cash used in financing activities | ($2,770) | ($2,863) | | **Net increase in cash and cash equivalents** | **$283** | **$1,239** | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes provide detailed explanations of the financial statements, including the basis of presentation, a significant restatement due to the Monogram Warrant valuation, customer concentration, share repurchase activities, and a material weakness in internal controls related to investment valuation - On October 6, 2023, the company exercised its Monogram Warrant in full for **$1,250,000**, receiving **1,828,551 shares** of Monogram common stock. The fair value is now reflected in marketable equity securities[40](index=40&type=chunk) Major Customer Concentration (Nine Months Ended March 31, 2024) | Metric | Customer 1 | Customer 2 | Total | | :--- | :--- | :--- | :--- | | % of Net Sales | 71% | 10% | 81% | | % of Accounts Receivable | 81% | 13% | 94% | - During the nine months ended March 31, 2024, the company repurchased **96,890 shares** of its common stock for an aggregate cost of **$1.83 million** under its share repurchase program[73](index=73&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=ITEM%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) Management discusses Q3 and 9M FY2024 financial results, highlighting revenue growth, gross margin improvement, increased expenses, investment loss impact on net income, and sufficient liquidity for strategic initiatives - The company's business strategy is focused on maintaining relationships with current medical device customers, expanding manufacturing capacity with the Franklin Property, and investing in R&D for new products like orthopedic shavers and screwdrivers[90](index=90&type=chunk) - As of March 31, 2024, the company had a sales backlog of approximately **$25.2 million**, with **$9.9 million** scheduled for delivery in the fourth quarter of fiscal 2024[96](index=96&type=chunk) [Results of Operations](index=25&type=section&id=Results%20of%20Operations) For the nine months ended March 31, 2024, net sales increased 9.6% to $38.8 million, driven by medical device sales, with gross profit up 11% to $10.5 million and operating income growing 16% to $4.8 million, despite a $3.8 million unrealized investment loss impacting pre-tax income Net Sales by Type (Nine Months Ended March 31, in thousands) | Sales Type | 2024 | 2023 | | :--- | :--- | :--- | | Medical device products | $26,536 | $23,631 | | NRE & Proto-type | $762 | $2,361 | | Repairs | $11,749 | $9,410 | | **Total Net Sales** | **$38,819** | **$35,448** | Medical Device Sales by Type (Nine Months Ended March 31, in thousands) | Device Type | 2024 | 2023 | | :--- | :--- | :--- | | Orthopedic | $17,136 | $15,271 | | CMF | $6,641 | $7,208 | | Thoracic | $2,759 | $1,152 | | **Total Medical Device Sales** | **$26,536** | **$23,631** | - Gross margin for the nine months ended March 31, 2024, increased by **1 percentage point** to **27%** compared to the prior year period[97](index=97&type=chunk)[101](index=101&type=chunk) - Research and development costs for the nine months ended March 31, 2024, increased by **12%** to **$2.4 million**, reflecting continued investment in product development efforts[104](index=104&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2024, the company had $3.2 million in cash and cash equivalents and working capital of $25.5 million, with management confident in sufficient liquidity from existing cash, operations, and available credit facilities for the next 12 months, managed by an Investment Committee Liquidity Summary (as of March 31, 2024, in thousands) | Metric | Amount | | :--- | :--- | | Cash and cash equivalents | $3,219 | | Working capital | $25,538 | - The company believes its existing cash, operational cash flows, and available credit will be sufficient to fund its requirements for at least the next **12 months**[123](index=123&type=chunk) - The company has an Investment Committee, chaired by Nicholas Swenson, to manage surplus operating capital or borrowed funds, investing in a portfolio of marketable public equity securities valued at **$6.1 million** as of March 31, 2024[125](index=125&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) This section is not applicable for the reporting period - The company has indicated that Quantitative and Qualitative Disclosures About Market Risk are not applicable[127](index=127&type=chunk) [Controls and Procedures](index=32&type=section&id=ITEM%204.%20CONTROLS%20AND%20PROCEDURES) Management, including the CEO and CFO, concluded that as of March 31, 2024, the company's disclosure controls and procedures were not effective due to an ongoing material weakness related to the valuation and disclosure of Level 2 and Level 3 investments - A material weakness was identified in internal control over financial reporting concerning the valuation and disclosure of level 3 investments during fiscal 2023 and level 2 investments for the quarter ended December 31, 2023. Remediation is ongoing[129](index=129&type=chunk) - Based on their evaluation, the Chief Executive Officer and Chief Financial Officer concluded that as of March 31, 2024, the company's disclosure controls and procedures were not effective[130](index=130&type=chunk) [PART II — OTHER INFORMATION](index=33&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) [Legal Proceedings](index=33&type=section&id=ITEM%201.%20LEGAL%20PROCEEDINGS) The company may be involved in various legal proceedings from time to time in the ordinary course of business, with further details referenced in Note 13 of the financial statements - Information regarding legal proceedings is referenced in Note 13 to the condensed consolidated financial statements[136](index=136&type=chunk) [Risk Factors](index=33&type=section&id=ITEM%201A.%20RISK%20FACTORS) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the fiscal year ended June 30, 2023 - No material changes have occurred in the risk factors as disclosed in the Annual Report on Form 10-K for the fiscal year ended June 30, 2023[138](index=138&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=34&type=section&id=ITEM%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS) During the quarter ended March 31, 2024, the company repurchased a total of 90,605 shares of its common stock at an average price of $19.01 per share under its publicly announced repurchase program Common Stock Repurchases for the Quarter Ended March 31, 2024 | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | January 2024 | 23,838 | $20.84 | | February 2024 | 34,565 | $19.10 | | March 2024 | 32,202 | $17.56 | | **Total** | **90,605** | **$19.01** | [Other Information](index=34&type=section&id=ITEM%205.%20OTHER%20INFORMATION) During the quarter ended March 31, 2024, no director or officer of the company adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement - No director or officer adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the third quarter of fiscal 2024[142](index=142&type=chunk) [Exhibits](index=34&type=section&id=ITEM%206.%20EXHIBITS) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications and XBRL data files